A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

December 30, 2027

Conditions

Solid Tumor CancerMetastatic Solid TumorsLocally Advanced

Interventions

DRUG

Observation arm

To observe the efficacy and safety of Iparomilimab and Tuvonralimab in the treatment of patients with solid tumors in the real world

Trial Locations (1)

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

PENG YUAN

OTHER